Elspar, Spectrila(asparaginase)
Elspar, Spectrila (asparaginase) is an enzyme pharmaceutical. Asparaginase was first approved as Elspar on 1978-01-10. It is used to treat cholelithiasis, lymphoma, and precursor cell lymphoblastic leukemia-lymphoma in the USA. It has been approved in Europe to treat precursor cell lymphoblastic leukemia-lymphoma.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| lymphoma | — | D008223 | C85.9 |
| precursor cell lymphoblastic leukemia-lymphoma | — | D054198 | — |
| cholelithiasis | EFO_0004799 | D002769 | K80 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
299 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 40 | 96 | 69 | 14 | 25 | 223 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 37 | 94 | 64 | 16 | 32 | 223 |
| Lymphoid leukemia | D007945 | — | C91 | 36 | 86 | 55 | 14 | 22 | 195 |
| Lymphoma | D008223 | — | C85.9 | 10 | 44 | 20 | 4 | 7 | 81 |
| T-cell lymphoma | D016399 | — | — | 5 | 15 | 2 | 3 | 4 | 27 |
| T-cell lymphoma peripheral | D016411 | — | — | 4 | 13 | 2 | 3 | 4 | 24 |
| Philadelphia chromosome | D010677 | — | — | 4 | 4 | 3 | 2 | — | 11 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 5 | 21 | 12 | — | 1 | 38 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 4 | 7 | 9 | — | — | 20 |
| Myeloid leukemia | D007951 | — | C92 | 3 | 6 | 8 | — | — | 17 |
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | 5 | 9 | 5 | — | — | 16 |
| Recurrence | D012008 | — | — | 6 | 9 | 2 | — | 1 | 15 |
| Extranodal nk-t-cell lymphoma | D054391 | — | C86.0 | 2 | 9 | 1 | — | 3 | 13 |
| Syndrome | D013577 | — | — | 2 | 1 | 6 | — | — | 9 |
| Myelodysplastic syndromes | D009190 | — | D46 | 2 | 1 | 6 | — | — | 9 |
| Acute disease | D000208 | — | — | 3 | 3 | 2 | — | — | 8 |
| Preleukemia | D011289 | — | — | 2 | — | 6 | — | — | 8 |
Show 30 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Biphenotypic leukemia acute | D015456 | — | C95.0 | 2 | 4 | — | — | — | 5 |
| Neoplasms | D009369 | — | C80 | 1 | 4 | — | — | — | 5 |
| Hematologic neoplasms | D019337 | — | — | 2 | 2 | — | — | — | 4 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | 1 | 1 | — | — | 2 | 4 |
| Pancreatitis | D010195 | HP_0001733 | K85 | 1 | 1 | — | — | 1 | 2 |
| T-cell leukemia | D015458 | — | — | 1 | 2 | — | — | — | 2 |
| Precursor b-cell lymphoblastic leukemia-lymphoma | D015452 | — | — | 1 | 2 | — | — | — | 2 |
| Healthy volunteers/patients | — | — | — | — | 1 | — | — | 1 | 2 |
| Urologic neoplasms | D014571 | — | C64-C68 | — | 1 | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | — | — | — | 1 |
Show 14 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
| Prolymphocytic leukemia t-cell | D015461 | — | C91.6 | 1 | — | — | — | — | 1 |
| Prolymphocytic leukemia | D015463 | — | — | 1 | — | — | — | — | 1 |
| Blast crisis | D001752 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | — | — | 2 | 2 |
| Ataxia | D001259 | — | R27.0 | — | — | — | — | 1 | 1 |
| Ataxia telangiectasia | D001260 | Orphanet_100 | G11.3 | — | — | — | — | 1 | 1 |
| Telangiectasis | D013684 | — | — | — | — | — | — | 1 | 1 |
| Cerebellar ataxia | D002524 | HP_0001251 | — | — | — | — | — | 1 | 1 |
| T-cell lymphoma cutaneous | D016410 | — | — | — | — | — | — | 1 | 1 |
| Hyperlipidemias | D006949 | HP_0003077 | E78.5 | — | — | — | — | 1 | 1 |
| Hyperlipoproteinemias | D006951 | HP_0010980 | — | — | — | — | — | 1 | 1 |
| Thromboembolism | D013923 | HP_0001907 | — | — | — | — | — | 1 | 1 |
| Residual neoplasm | D018365 | — | — | — | — | — | — | 1 | 1 |
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Asparaginase |
| INN | crisantaspase |
| Description | Asparaginase is an enzyme that is used as a medication and in food manufacturing. As a medication, L-asparaginase is used to treat acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available. In food manufacturing it is used to decrease acrylamide.
|
| Classification | Enzyme |
| Drug class | enzymes |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 12,108 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10,777 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use